Inside Innovation

OpenAI has entered a new collaboration with Lundbeck to expand the use of large language models in pharmaceutical research and drug development. Lundbeck, a global

AGC Biologics has partnered with Rarity PBC to develop and manufacture RDP-101, a gene therapy designed to treat adenosine deaminase severe combined immunodeficiency disorder (ADA-SCID),

In an interview with GEN, Nobel Laureate David Baker, PhD, director of the Institute for Protein Design at the University of Washington, reflected on the

Samsung has acquired Seattle-based digital health startup Xealth for approximately $115 million, marking a significant expansion of the tech giant’s push into digital healthcare. Founded

Pfizer and Astellas, in partnership with Merck & Co., reported that the antibody-drug Padcev and the immunotherapy Keytruda reduced the risk of death by 50

Seattle-area health technology startup Brook.ai has raised $28 million in Series B funding to expand its AI-driven remote care platform that helps patients manage chronic

Novo Nordisk has acquired rights to Omeros’ MASP-3 inhibitor zaltenibart, a rare-disease therapy, in a deal worth up to $2.1 billion, including $340 million in

Life Science Washington and Madrona hosted the AI Leadership Forum in Seattle to explore how artificial intelligence is transforming drug discovery, biomanufacturing, and healthcare. The

Riverside Biotech Hub, a new biotech incubator launched earlier this year in downtown Spokane, is expanding access to wet lab facilities and equipment for early-stage

Researchers have used an AI model to generate a remarkably detailed map of the mouse brain, identifying around 1,300 distinct regions and subregions. The effort,

Bristol Myers Squibb announced that it will acquire Orbital Therapeutics to expand and diversify its cell therapy portfolio. The acquisition includes Orbital’s lead RNA immunotherapy